Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.

about

Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification.

Item

http://www.wikidata.org/entity/Q48148198

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Pathological response in a tri ...... mann's refined classification.

@en

Pathological response in a tri ...... mann's refined classification.

@nl

type

Item

label

Pathological response in a tri ...... mann's refined classification.

@en

Pathological response in a tri ...... mann's refined classification.

@nl

prefLabel

Pathological response in a tri ...... mann's refined classification.

@en

Pathological response in a tri ...... mann's refined classification.

@nl

P1476

Pathological Response in a Tri ...... hmann's Refined Classification

@en

P2093

Agusti Barnadas

http://www.w3.org/2001/XMLSchema#string

Ana Isabel Ballesteros

http://www.w3.org/2001/XMLSchema#string

Enrique Alvarez

http://www.w3.org/2001/XMLSchema#string

Fernando Moreno

http://www.w3.org/2001/XMLSchema#string

Henry L Gómez

http://www.w3.org/2001/XMLSchema#string

Hugo Fuentes

http://www.w3.org/2001/XMLSchema#string

Inmaculada Ocaña

http://www.w3.org/2001/XMLSchema#string

Isabel Echavarria

http://www.w3.org/2001/XMLSchema#string

Javier Gayarre

http://www.w3.org/2001/XMLSchema#string

María Cebollero

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular portraits of human breast tumours

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40

Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.

P304

1845-1852

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-17-1912

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29378733

http://www.w3.org/2001/XMLSchema#string

P932

5899625

http://www.w3.org/2001/XMLSchema#string